Physician profile
John Wells
NPI 1043214422
$4,982.58
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $556 · 2021: $1,495 · 2022: $1,398 · 2023: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,095.12 | 2019-2023 | Skyrizi, Mavyret, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $539.16 | 2019-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $510.22 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $500.52 | 2019-2023 | |
| Janssen Biotech, INC. | $421.98 | 2019-2023 | Stelara |
| E.R. Squibb & Sons, L.L.C. | $375.87 | 2022-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $331.10 | 2019-2022 | |
| Celgene Corporation | $166.75 | 2021-2023 | Zeposia |
| Redhill Biopharma INC. | $156.82 | 2020-2023 | Movantik, Aemcolo, Talicia |
| Merck Sharp & Dohme LLC | $138.63 | 2019-2022 | |
| Ucb, INC. | $121.08 | 2019 | |
| Pfizer INC. | $120.93 | 2019-2021 | |
| Acell, INC. | $100.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $79.68 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $73.83 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $58.69 | 2022-2023 | Cimzia |
| Shionogi INC | $55.96 | 2019 | |
| Allergan, INC. | $44.94 | 2019 | |
| Ardelyx, INC. | $42.84 | 2022 | |
| Medtronic, INC. | $18.88 | 2022 | |
| Braintree Laboratories, INC. | $16.17 | 2023 | Sutab |
| Horizon Therapeutics Plc | $13.41 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,901.71 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.